Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Ann Surg. 2021 Jun 16;276(6):e876–e885. doi: 10.1097/SLA.0000000000004993

Figure 2. Clinical training and validation of establishes an EMP for predicting recurrence following surgery in patients with PDAC.

Figure 2.

(A) ROC curve of the pre-treatment 6-exo-miRNA EMP recurrence prediction model constructed using cox regression with backward elimination for feature selection using the training cohort (AUC = 0.81). (B) Distribution of risk scores according to recurrence status (P < 0.01, Mann Whitney test). (C) The new combination model, EMP and CA19-9, outperformed the prediction accuracy of other variables in the training cohort (AUC = 0.84). (D) ROC curves of the 6-exo-miRNA EMP derived from the training cohort for recurrence prediction in an independent validation cohort (AUC = 0.78). (E) Distribution of risk scores according to recurrence status (P < 0.01, Mann Whitney test). (F) ROC curves showing the recurrence predictive performance of the combination model, EMP and CA19-9, compared to conventional clinical factors in the validation cohort (AUC = 0.82).